Mechanisms of chemotherapy resistance in ovarian cancer | Zendy

Mylena Ortiz | Zendy; Emma Wabel | Zendy; Kerry Mitchell | Zendy; Sachi Horibata | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mechanisms of chemotherapy resistance in ovarian cancer

Author(s) -

Mylena Ortiz,

Emma Wabel,

Kerry Mitchell,

Sachi Horibata

Publication year - 2022

Publication title -

cancer drug resistance

Language(s) - English

Resource type - Journals

ISSN - 2578-532X

DOI - 10.20517/cdr.2021.147

Subject(s) - ovarian cancer , olaparib , bevacizumab , medicine , paclitaxel , chemotherapy , oncology , vascular endothelial growth factor , drug resistance , cancer research , pharmacology , cancer , poly adp ribose polymerase , polymerase , vegf receptors , biology , dna , microbiology and biotechnology , genetics

Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (olaparib and niraparib) and one vascular endothelial growth factor inhibitor (bevacizumab) as maintenance therapies for ovarian cancer. In this review, we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research